- ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
American Board of Internal Medicine
St. Mary's Hospital
* Beth Israel Medical Center *
- coming soon
LarynxI have been involved in several clinical trials for the treatment of Head and Neck Cancer.
We have a multidisciplenary treatment approach to all sites of head and neck cancer.
Cuurent trials include postoperative chemotherapy and radiation for intermediate and high risk disease.
Patel S, Mourad WF, Wang C, Dhanireddy B, Concert C, Ryniak M, Khorsandi AS, Shourbaji RA, Li Z, Culliney B, Patel R, Bakst RL, Tran T, Shasha D, Schantz S, Persky MS, Hu KS, Harrison LB. Postoperative radiation therapy for parotid pleomorphic adenoma with close or positive margins: treatment outcomes and toxicities. Anticancer research 2014 Aug; 34(8).
Mourad WF, Hauerstock D, Shourbaji RA, Hu KS, Culliney B, Li Z, Jacobson A, Tran T, Manolidis S, Schantz S, Urken M, Persky M, Harrison LB. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. American journal of clinical oncology 2013 Dec; 36(6).
Mourad WF, Hu KS, Shasha D, Concert C, Ishihara D, Lin W, Gamez ME, Lukens JN, Lukens JJ, Shourbaji RA, Ryniak M, Li Z, Culliney BE, Khorsandi AS, Tran T, Jacobson A, Manolidis S, Schantz S, Urken M, Persky MS, Harrison LB. Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy. Anticancer research 2013 Dec; 33(12).
Visnyei K, Gill R, Azizi E, Culliney B. Squamous cell carcinoma of the external auditory canal: A case report and review of the literature. Oncology letters 2013 May; 5(5).
Mourad WF, Hu KS, Puckett L, Hauerstock D, Shourbaji RA, Li Z, Manolidis S, Schantz S, Tran T, Jacobson A, Urken M, Culliney B, Persky M, Harrison LB. Five-year outcomes of squamous cell carcinoma of the tonsil treated with radiotherapy. American journal of clinical oncology 2014 Feb; 37(1).
Mourad WF, Hu KS, Shasha D, Concert C, Ishihara D, Lin W, Shourbaji RA, Ryniak M, Gamez ME, Lukens JN, Li Z, Culliney BE, Khorsandi AS, Tran T, Jacobson A, Manolidis S, Schantz S, Urken M, Persky MS, Harrison LB. Initial experience with oropharynx-targeted radiation therapy for metastatic squamous cell carcinoma of unknown primary of the head and neck. Anticancer research 2014 Jan; 34(1).
Haigentz M, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral oncology 2012 Dec; 48(12).
Culliney B, Birhan A, Young AV, Choi W, Shulimovich M, Blum RH. Management of locally advanced or unresectable head and neck cancer. Oncology (Williston Park, N.Y.) 2008 Sep; 22(10).
Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J, Portenoy RK, Esteban-Cruciani N. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. Journal of pain and symptom management 2009 Apr; 37(4).
Cruciani RA, Dvorkin E, Homel P, Malamud S, Culliney B, Lapin J, Portenoy RK, Esteban-Cruciani N. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. Journal of pain and symptom management 2006 Dec; 32(6).
Frank DK, Hu KS, Culliney BE, Persky MS, Nussbaum M, Schantz SP, Malamud SC, Holliday RA, Khorsandi AS, Sessions RB, Harrison LB. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. The Laryngoscope 2005 Jun; 115(6).
Parikh RR, Moskowitz BK, Maher E, Della Rocca D, Della Rocca R, Culliney B, Shapira I, Grossbard ML, Harrison LB, Hu K. Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy. Leukemia & lymphoma 2015 Jan;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Culliney did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Mount Sinai Beth Israel Cancer Center
10 Union Square East, Ste 4A, 4C
New York, NY 10003